Here is a lot of research on tesamorelin:
Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. PMID:
Julian Falutz, M.D., Soraya Allas, M.D., Ph.D., Koenraad Blot, M.D., Diane Potvin, M.Sc., Donald Kotler, M.D., Michael Somero, M.D., Daniel Berger, M.D., Stephen Brown, M.D., Gary Richmond, M.D., Jeffrey Fessel, M.D., Ralph Turner, Ph.D., M.P.H., and Steven Grinspoon, M.D. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. December 6, 2007
N Engl J Med 2007; 357:2359-2370. DOI: 10.1056/NEJMoa072375
Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PMID: 22495074; PMCID: PMC3348954.
Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of neurology, 69(11), 1420–1429. Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial
Adrian, S., Scherzinger, A., Sanyal, A. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154–159 (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV - The Journal of Frailty & Aging
Dhillon, S. Tesamorelin. Drugs 71, 1071–1091 (2011). https://doi.org/10.2165/11202240-000000000-00000
Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf
Friedman SD, Baker LD, Borson S, et al. Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425
Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043.
Patel A, Gandhi H, Upaganlawar A. Tesamorelin: A hope for ART-induced lipodystrophy. J Pharm Bioallied Sci. 2011;3(2):319-320. doi:10.4103/0975-7406.80763
Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: Executive Summary - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf
Sami H. Tuffaha, Prateush Singh, Joshua D. Budihardjo, Kenneth R. Means, James P. Higgins, Jaimie T. Shores, Roberto Salvatori, Ahmet Höke, W.P. Andrew Lee & Gerald Brandacher (2016) Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury, Expert Opinion on Therapeutic Targets, 20:10, 1259-1265, DOI: 10.1080/14728222.2016.1188079
